The FDA declined to approve one of biotech’s most closely watched cancer drugs. The company’s stock tumbled.
Source: MarketWatch ·
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Read the full story at MarketWatch
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.